Paclitaxel, Carboplatin

DRUG5 trials

Sponsors

Queensland Centre for Gynaecological Cancer, Korean Gynecologic Oncology Group, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Institute and Hospital, Fudan University

Conditions

Breast CancerCervical CancerMetastatic Breast CancerOvarian CancerUterine Cancer

Phase 2

Uterine Papillary Serous Cancer (UPSC) Trial

CompletedNCT00147680

Queensland Centre for Gynaecological CancerUterine Cancer

Start: 2004-09-30End: 2009-10-31Target: 30Updated: 2012-02-02

A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients

CompletedNCT00340184

Korean Gynecologic Oncology GroupCervical Cancer

Start: 2004-08-31Target: 55Updated: 2010-10-19

Weekly Paclitaxel Plus Carboplatin in Preoperative Treatment of Breast Cancer

CompletedNCT01203267

Shanghai Jiao Tong University School of MedicineBreast Cancer

Start: 2007-12-31End: 2008-12-31Updated: 2010-09-16

Phase 3

Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer

Fudan UniversityOvarian Cancer

Start: 2021-07-16End: 2023-12-31Target: 200Updated: 2022-05-12

Phase 4

Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer

Tianjin Medical University Cancer Institute and HospitalMetastatic Breast Cancer

Start: 2013-12-31End: 2016-12-31Target: 120Updated: 2015-12-22

Related Papers

Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.

Journal of Clinical Oncology2017-05-20